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Therapy-related ALL (t-ALL) is a rare secondary leukemia that develops after chemotherapy and/or radiotherapy for primary malig-
nancies. Chromosomal 11q23 abnormalities are the most common karyotypic alterations in t-ALL. The t(11;19)(q23;p13) aberration 
is extremely rare and has not been confirmed at the molecular genetic level. Here, we report a case of t-ALL with t(11;19)(q23;p13.3) 
and MLL-MLLT1 (alias ENL) gene rearrangement confirmed by cytogenetic analysis, multiplex reverse transcription-PCR (multiplex 
RT-PCR), and DNA sequencing in a patient who had undergone treatment for breast cancer. A 40-yr-old woman developed acute 
leukemia 15 months after undergoing 6 cycles of adjuvant chemotherapy (doxorubicin 60 mg/m
2 and cyclophosphamide 600 
mg/m
2), radiation therapy (dose, 5,900 cGy), and anticancer endocrine therapy with tamoxifen. The complete blood cell counts 
and bone marrow examination showed increased blasts and the blasts showed B lineage immunophenotype (positive for CD19, 
CD34, and cytoplasmic CD79a). Cytogenetic analysis revealed the karyotype 47,XX,+X,t(11;19)(q23;p13.3)[4]/46,XX[16]. FISH analy-
ses, multiplex RT-PCR, and DNA sequencing confirmed the MLL-MLLT1 gene rearrangement. The patient underwent induction che-
motherapy with fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) and achieved com-
plete remission. Subsequently, she underwent consolidation chemotherapy, but died of brain ischemia in the pons and the region 
of the middle cerebral artery. To our knowledge, this is the first case report of t-ALL with t(11;19)(q23;p13.3) and the MLL-MLLT1 
gene rearrangement.
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INTRODUCTION
Therapy-related acute leukemia (t-AL) is a rare second-
ary leukemia that develops after chemotherapy and/or ra-
diotherapy for primary malignancies. It can be broadly di-
vided into 2 major groups: alkylating agent/radiotherapy-
related t-AL and topoisomerase II inhibitor-related t-AL. 
Patients in the alkylating agent-related t-AL subgroup fre-
quently exhibit complete or partial deletion of chromosome 
5 or 7 and generally have antecedent myelodysplasia with a 
mean latency period of 5–7 yr [1]. In contrast, patients in 
the DNA topoisomerase II inhibitor-related t-AL subgroup 
generally develop secondary leukemia with relatively short 
latency periods (1–5 yr). The most common characteristic 
chromosomal aberrations in this group are translocations 
involving 11q23, i.e., the mixed lineage leukemia (MLL) 
gene locus [1]. Therapy-related ALL (t-ALL) is much less 
frequent than therapy-related AML (t-AML) and accounts 
for approximately 12% of all t-AL cases and 1.2–4% of adult 
ALL cases [2, 3].
Chromosomal 11q23 abnormalities are considered the 
most common karyotypic alterations with a frequency of 
up to 46% in t-ALL; the most common abnormality is 
t(4;11)(q21;q23) [2, 4].
Here, we report a case of t-ALL with t(11;19)(q23;p13.3) 
and the MLL-MLLT1 (alias ENL) gene rearrangement con-
firmed by cytogenetic analysis, multiplex reverse transcrip-14     www.kjlm.org
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tion-PCR (multiplex RT-PCR), and DNA sequencing in a 
patient who had undergone treatment for breast cancer. To 
our knowledge, this is the first report of t-ALL with the 
MLL-MLLT1 gene rearrangement.
CASE REPORT
A 40-yr-old woman underwent breast surgery for cancer 
of the right breast and received 6 cycles of adjuvant chemo-
therapy (doxorubicin 60 mg/m
2 and cyclophosphamide 600 
mg/m
2) and radiation therapy (dose, 5,900 cGy), followed 
by anticancer endocrine therapy with tamoxifen. Complete 
blood cell counts obtained at 15 months after chemotherapy 
indicated acute leukemia: white blood cell count, 3.5 × 10
9/
L with 15% blasts; Hb level, 5.8 g/dL; and platelet count, 
31.0 × 10
9/L. Bone marrow examination showed hypercel-
lular marrow with increased blasts, accounting for up to 95% 
of all bone marrow nucleated cells (Fig. 1). An immuno-
phenotyping study using flow cytometry revealed that the 
blasts were positive for CD19, CD34, and cytoplasmic CD79a 
and negative for CD2, CD3, CD5, CD7, CD10, CD13, CD14, 
CD20, CD22, CD33, CD41, CD117, and myeloperoxidase. 
On the basis of the immunophenotype of the blasts, we di-
agnosed the patient with B-ALL. Cytogenetic analysis of the 
bone marrow aspirates by using the G-banding revealed the 
karyotype 47,XX,+X,t(11;19)(q23;p13.3)[4]/46,XX[16] (Fig. 
2). FISH performed using LSI MLL dual color, break apart 
rearrangement probes (Abbott Molecular, Des Plaines, IL, 
USA) showed an MLL break apart signal in 76.2% of the 500 
analyzed cells (Fig. 3). The MLL-MLLT1 gene rearrange-
ment was confirmed by multiplex RT-PCR using the He-
maVision kit (DNA Technology, Research Park, Aarhus, 
Denmark). However, 2 different amplicons (319 bp and 432 
bp) were observed, and we identified the 2 amplicons by 
DNA sequencing. Both amplicons contained a t(11;19)
(q23;p13.3)(MLL; MLLT1) translocation (Fig. 4). The patient 
underwent induction chemotherapy with Hyper-CVAD 
from March 2010. Complete remission was noted on the fol-
low-up bone marrow study, and no MLL gene rearrangement 
was observed on follow-up FISH analysis. Subsequently, she 
underwent consolidation chemotherapy until June 2010; 
however, she died because of brain ischemia in the pons and 
the region of the middle cerebral artery.
Fig. 1. Morphologic findings of B-ALL in the bone marrow. (A) Bone marrow aspirate smear shows moderate- to large-sized blasts with cytoplasmic vacuolation 
(Wright-Giemsa stain, ×1,000). (B) Bone marrow biopsy shows almost complete replacement of hypercellular marrow by blasts (hematoxylin and eosin stain, 
×100).
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Fig. 2. G-banding of a bone marrow cell showing a 47,XX,+X,t(11;19)
(q23;p13.3)[4]/46,XX[16] karyotype.
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DISCUSSION
MLL rearrangement is one of the most frequently ob-
served genetic abnormalities in patients with t-ALL. Ac-
cording to a study summarizing t-ALL cases reported in the 
literature from 1992 to 2007, in 48 cases of t-ALL, an 11q23 
abnormality involving the MLL gene locus was the pre-
dominant chromosomal aberration (32/48 [67%]), followed 
by t(9;22) (6/48 [13%]) and a normal karyotype (4/48 [8%]) 
[5]. On comparing t-ALL cases with/without 11q23 abnor-
malities (MLL group or non-MLL group), the distribution 
of primary malignancies between the 2 groups appeared to 
be fairly variable. Hematologic malignancies (mainly Hodg-
kin’s lymphoma) were the most common primary neo-
plasms in the non-MLL group (7/16 [44%]), whereas breast 
cancer was the most frequent primary tumor in the MLL 
group (12/32 [38%]). The latency period between the pri-
mary malignancy and t-ALL in the non-MLL group was 
much longer than that in the MLL group (median, 36 vs. 19 
months) [5]. A relatively short latency period, ranging from 
12 months to 22 yr with a median latency of 16 months, has 
Fig. 3. Interphase FISH using the LSI MLL dual color, break apart rearrange-
ment probe (Abbott) set. Interphase nucleus harboring the MLL transloca-
tion, 1 fusion signal, and 2 separate signals (1F1O1G).
Fig. 4. MLL1/ENL fusion transcript identified by multiplex reverse transcription-PCR. (A) Amplification products of 8 parallel multiplex reverse transcription-PCR 
reactions. Two bands (319 bp and 432 bp; arrow heads) are noted in lane 3. (B) Corresponding split-out reactions. Two positive bands in lane D represent the fusion 
transcript MLL1/ENL [t(11;19)(q23;p13.3)]. (Lanes 1 and A, 100-bp DNA ladder) (C) Part of the sequence from the 319-bp amplicon from lane D shows t(11;19)
(q23;p13.3) MLL exon 9/MLLT1 exon 2. (D) Part of the sequence from the 432-bp amplicon from lane D shows t(11;19)(q23;p13.3) MLL exon 10/MLLT1 exon 2; pink, 
MLL exon 8; yellow, MLL exon 9; blue, MLL exon 10; green, 5’ end of MLLT1 exon 2.
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been reported in cases of t-ALL with MLL [4]. The primary 
malignancy in the present case was breast cancer, and the 
latency period was relatively short; this was compatible with 
the majority of previous findings for the MLL group. No 
significant differences were noted in the chemotherapy regi-
men or survival between the 2 groups.
The MLL gene on chromosome 11q23 is known to have 
several fusion partners. The most common partner gene is 
AFF1 (alias AF4) on chromosome 4q21; other common 
partner genes include MLLT1 (alias ENL) on chromosome 
19p13 and MLLT3 (alias AF9) on chromosome 9p22 [6].
The aberration t(4;11)(q21;q23) was noted in 67–89% of 
MLL-positive t-ALL cases, and the aberration t(1;11)(q21; 
q23) was observed in 9–11% of cases [2, 4, 7, 8]. To date, 
only 2 cases of the aberration t(11;19)(q23;p13), i.e., involv-
ing chromosome 19p13 similar to the present case, have 
been reported (Table 1) [9, 10].
The breakpoint on chromosome 19 is variable [11] and 
can occur at either p13.1 or p13.3 [12-14]. Three MLL part-
ner genes on 19 p13 have been identified: ELL at 19p13.1, 
MLLT1 at 19p13.3, and SH3GL1 (alias EEN) on 19p13.3. A 
report evaluating hematologic malignancy involving chro-
mosome 11q23 and chromosome 19p13 showed marked 
differences between t(11;19)(q23;p13.1) and t(11;19)(q23; 
p13.3) [15]. Patients with t(11;19)(q23;p13.1) mostly had 
myeloid lineage leukemia with rare additional chromosomal 
changes and were predominantly adults. In contrast, patients 
with t(11;19)(q23;p13.3) had both myeloid and lymphoid 
lineage malignancy with up to 50% additional chromosomal 
changes and were mostly infants less than 1 yr of age. At 
times, the identification of the breakpoint on 19p13 by us-
ing conventional G-banding may be difficult; therefore, in 
the case of MLL rearrangement involving 19p13, further 
specific banding techniques and molecular genetic testing 
must be performed to identify MLL abnormalities. In this 
patient too, the breakpoint on G-banding was unclear; there-
Table 1. Characteristics of the therapy-related ALL cases with t(11;19) abnormalities reported since 1992
Reference
Age/
Gen-
der
Primary malignancy Previous treat-
ment
Secondary 
malignancy
Latency period 
(months) Karyotype Immunophenotype
Kobayashi et al. (1993) [10] 44/F Breast cancer Flu, Pirub B-ALL 19 46XX,t(11;19)(q23;p13) CD10-, CD19+, CD20-, 
HLA-DR+
Thandla et al. (1999) [9] 10/M Hepatocellular carcinoma Dox, Cis, Etop, 
Carbo, Ifos
T-ALL 48 t(1;13)(q4;q13), 
t(11;19),+X,+5,+8,+13,+14
CD3-, CD4+, CD8+, CD2+, 
CD7+, CD5+, CD56+
Present case (2010) 40/F Breast cancer Dox, Ctx, RT, Tmf B-ALL 15 47,XX,+X,t(11;19)(q23;p13.3) CD10-, CD19+, CD20- , 
CD22-, CD34+, cCD79a+
Abbreviations: Flu, fludarabine; Pirub, pirarubicin; Dox, doxorubicin; Cis, cisplatin; Etop, etoposide; Carbo, carboplatin; Ifos, ifosfamide; Ctx, cyclophosphamide; RT, radiotherapy; 
Tmf, tamoxifen.
fore, we performed multiplex RT-PCR and thereby identi-
fied the MLL-MLLT1 rearrangement. Previously reported t-
ALL cases with the aberration t(11;19)(q23;p13) had not 
been further confirmed at the molecular level, i.e., the re-
gion of p13 on chromosome 19 that was involved was not 
clarified [9, 10].
Among patients with acute leukemia and MLL rearrange-
ments, approximately 10% have been shown to have the 
MLL/MLLT1 rearrangement. Fu et al. [16] reported the fre-
quency of the MLL/MLLT1 rearrangement to be 3.5% 
(4/114) in MLL-positive de novo AML, 23% (7/30) in MLL-
positive de novo B-ALL, and 100% (4/4) in MLL-positive de 
novo T-ALL. Therefore, the incidence of MLL/MLLT1 rear-
rangement in t-ALL is significantly lower than that in de 
novo ALL.
The presence of the MLL/MLLT1 rearrangement appears 
to have certain clinical implications, such as on the progno-
sis. For example, non-infants with the B-ALL and the MLL/
MLLT1 rearrangement have a favorable prognosis [17-21], 
whereas the prognosis of infants with B-ALL and the MLL/
MLLT1 rearrangement is controversial [16, 17]. Further 
studies are essential for clarifying the clinical implications 
of MLL/MLLT1 rearrangement in t-ALL patients.
In a majority of t-ALL cases with the MLL rearrangement, 
the leukemic cells typically have a pro-B immunophenotype 
and are positive for CD19 and the aberrant expression of 
CD15 and CD65 and are negative for CD10 and CD24 pat-
terns [6, 8, 11]. Our patient too showed a CD19-positive 
and CD10-negative immunophenotype; however, we did 
not evaluate the CD15 and CD24 immunophenotypes.
In summary, to the best of our knowledge, this is the first 
case of t-ALL with the aberration t(11;19)(q23;p13.3) and 
the MLL/MLLT1 rearrangement that was confirmed by 
molecular genetic testing; moreover, this case exhibited fea-
tures of a CD10-negative pro-B immunophenotype similar 
to other cases with the MLL rearrangement.Yoo B-J, et al.  •  t-ALL with MLL/MLLT1 Gene Rearrangement
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